IQWiG methods for RWE collection for products of same active ingredient class
Recently, I have written about RWE collection, that can be mandated by the G-BA as part of their benefit assessment. Now, the
Category: News and updates
G-BA defines 4 strict requirements on cefiderocol use to protect its “reserve antibiotics” status
Currently, reserve antibiotics are excluded from a benefit assessment by the G-BA. The G-BA decides whether to accept a new antibiotic onto the
Virtual consultations for patients with Covid-19 requiring intensive care introduced into routine clinical practice
During the pandemic, the G-BA introduced special regulations for hospital care. Based on their good experiences with these, the G-BA has now
KBV and GKV-SV agreed new clinician fees for DiGAs in Germany
From medical devices last week, we are moving back to digital health applications (DiGAs), and how clinician fees are set for these
Will the EU regulation for medical devices result in withdrawals or shortages?
Hi again! This week I am switching it up a bit, and look at medical devices, particularly the EU regulation for medical